WEBINAR ON DEMAND
Duration: 1 hour 15 minutes

Gene therapies are still relatively new as compared with traditional biologics and have yet to establish standard processing platforms that ensure their sustainability. This, in combination with the complex relationship between process and product, has resulted in a high level of risk adversity when considering alternate manufacturing technologies.

Significant advances have been made in moving away from labor-intensive, non-scalable processing steps; however, additional improvements will be required for these therapies to reach their full potential. The need to establish early proof of concept in the clinic and be first to market with a single-dose curative therapy puts extreme timeline pressure on gene therapies. For this reason, any process changes and new technologies present a risk-reward profile that requires careful consideration by therapy developers.

How do we work together as an industry to enable adoption of more scalable and commercially viable manufacturing processes in the context of these unique challenges? 

Please join us for a webinar with experts from Latham Biopharm, Siren Biotechnology, and Cytiva as they discuss how to navigate process changes and new technology as we move towards a new generation of AAV manufacturing. We’ll discuss:

• The evolution of AAV manufacturing – past, present, and future
• Where we can have the most impact with near and longer term process changes – where are the big wins?
• Managing the regulatory landscape for process changes or adopting new manufacturing technologies
• How we can collaborate as an industry to get to the next level

SPEAKERS

Sybil Danby
Global Commercial Leader, Viral Vectors
Cytiva

Clive Glover
Vice President and General Manager, Viral Vectors
Cytiva

Nathalie Clément
Vice President of Vector Development
Siren Biotechnology

Joseph Rininger
Managing Director
Latham Biopharm